Sinovac Receives Higher Privatization Offer

Only a few days after Sinovac Biotech announced a management-led group offered $6.18 per share to take the company private, a consortium of outside investors and pharmas topped the offer with a $7 per share bid to acquire the company. The outside group's offer is 13% higher than management's and values Sinovac, a Beijing vaccine company, at $390 million. Sinovac reported only $65 million in revenues and a small loss over the previous 12 months. EBITDA was $10 million. More details.... Stock Symbol: (NSDQ: SVA) Share this with colleagues: // //